cyclosporin-g has been researched along with Cadaver* in 3 studies
3 trial(s) available for cyclosporin-g and Cadaver
Article | Year |
---|---|
A clinical trial of cyclosporine G in cadaveric renal transplantation.
Cyclosporine G (OG 37-324) reportedly is an efficacious immunosuppressant with less nephrotoxicity than cyclosporine A. This is a prospective randomized double-blinded trial comparing cyclosporine G and cyclosporine A in cadaveric renal transplantation. Patient and graft survival, as well as major infectious complications, were not different between the two groups. Objective parameters of renal function, including serum creatinine, creatinine clearance, and inulin clearance, were routinely performed. These generally demonstrated less nephrotoxicity in those patients treated with cyclosporine G compared with cyclosporine A. Minor elevations of alanine aminotransferase were noted in the cyclosporine G-treated patients but this was not associated with acute morbidity. Overall, cyclosporine G appears to be equally as effective as cyclosporine A, but demonstrated notably less nephrotoxicity. Topics: Adult; Aged; Cadaver; Cyclosporine; Double-Blind Method; Female; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Diseases; Kidney Function Tests; Kidney Transplantation; Kidney Tubular Necrosis, Acute; Male; Middle Aged; Prospective Studies; Tissue Donors | 1995 |
Trial of cyclosporine vs OG37-325 in cadaveric renal transplantation: a preliminary report.
Topics: Cadaver; Cyclosporine; Cyclosporins; Female; Graft Survival; Humans; Immunosuppressive Agents; Kidney Function Tests; Kidney Transplantation; Male; Survival Analysis; Tissue Donors | 1993 |
A randomized, prospective, double-blinded trial of cyclosporine vs. OG37-325 in cadaveric renal transplantation--a preliminary report.
The efficacy of cyclosporine is documented, but it has side effects that are troublesome. Another compound, OG37-325, has been identified that appears to have similar efficacy, but less nephrotoxicity. This study was designed to address the benefits and toxicities of cyclosporine and OG37-325 in a prospective, randomized, double-blinded trial in cadaveric renal transplant recipients. The preliminary results demonstrate similar outcomes in terms of patient and graft survival, but suggest less nephrotoxicity in the OG37-325-treated patients. Longer follow-up will delineate the utility of OG37-325 in solid-organ transplantation. Topics: Adult; Cadaver; Cyclosporine; Cyclosporins; Double-Blind Method; Female; Graft Survival; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged | 1993 |